MOUNJARO® 12.5mg KwikPen®, 1 Stk.

MOUNJARO® 12.5mg KwikPen® is a multi-dose injection pen delivering 12.5 mg tirzepatide per 0.6 mL subcutaneous dose once weekly. Each pen contains 50 mg tirzepatide in 2.4 mL (approx. 20.8 mg/mL) and provides 4 weekly administrations. It acts as a dual GIP and GLP-1 receptor agonist, targeting both glucose regulation and weight control. The solution appears clear and nearly colorless to light yellow, suitable for injection in the abdomen, thigh, or upper arm.

• Per injection: 12.5 mg tirzepatide = 0.6 mL

• Pen content: 50 mg in 2.4 mL

• Strength: 20.8 mg/mL

• Mechanism: Dual GIP/GLP-1 agonist

• Injection areas: abdomen, thigh, upper arm

The pen provides a weekly fixed dose and may be part of gradual dose escalation. Each injection delivers the full 12.5 mg.

• Initiation: Begin at 2.5 mg weekly, step up in 2.5 mg increments every 4 weeks

• Maintenance: 5 mg, 10 mg, or 15 mg recommended; 12.5 mg is an intermediate titration step

• Weekly routine: Same day each week; may adjust if ≥3 days apart

• Missed dose: If missed within 4 days, inject ASAP; if longer, skip

• Injection process: Prime, dial to 1, inject 0.6 mL, hold 5 sec

• Rotate sites: Never inject at the same exact location consecutively

Indicated for adults with type 2 diabetes or for weight reduction/management in appropriate BMI ranges. Always combined with diet and exercise.

• Type 2 diabetes: For patients unable to use metformin, or as add-on therapy

• Weight management: For adults with BMI ≥30, or ≥27 with comorbidities

• Contraindications: Hypersensitivity to tirzepatide or excipients

• Cautions: History of pancreatitis, severe GI issues, or advanced diabetic retinopathy

• Pregnancy: Avoid use; discontinue ≥1 month prior to conception

• Side effects (common): Nausea, vomiting, diarrhoea, abdominal pain, constipation

Each 0.6 mL dose provides 12.5 mg tirzepatide. Pens contain 2.4 mL (50 mg total).

• Active ingredient: tirzepatide 12.5 mg

• Total pen amount: 50 mg/2.4 mL

• Excipients: Includes benzyl alcohol ~5.4 mg per dose

• Sodium level: <1 mmol (23 mg), essentially sodium-free

• Appearance: Clear to slightly yellow solution

Packaged with usage instructions and necessary leaflets, though pen needles are not provided.

• Pre-filled KwikPen®: 4 pre-measured weekly doses

• Included: Patient Information Leaflet and Instructions for Use

• Needles: Not supplied; must be sourced separately

Yes—most commonly gastrointestinal events and injection-site reactions. Side effects are often transient and dose-related.

• GI effects: Very frequent, esp. during titration (nausea, diarrhoea, vomiting)

• Discontinuations: Up to 6% stopped due to GI issues in higher doses

• Hypoglycaemia: Risk higher when combined with sulphonylurea/insulin

• Injection-site: Redness/itching reported in up to 8%

• Gallbladder events: Up to 2%

• Rare: Pancreatitis, hypersensitivity

Storage must follow refrigeration and disposal guidelines. Once opened, pens should not exceed their shelf-life.

• Unused pens: Refrigerate at 2–8°C; never freeze

• After first use: May store at ≤30°C, discard after 30 days

• Do not reuse: Dispose of after 4 weekly injections

• Needle safety: Remove and discard in sharps container after each dose

• Keep away from children